Low dose prednisolone reduces CD4+ T cell loss in therapy-naive HIV-patients without antiretroviral therapy

European Journal of Medical Research

Volumn 10, Issue 3, 2005, Pages 105-109

  Ulmer, Albrecht ^a   Muller M ^a   Bertisch Mollenhoff B ^a   Frietsch, B ^a  

^a HIV Schwerpunktpraxis   (Germany)

Author keywords

Antiretroviral therapy; CD4+ T cell; Corticosteroids; HIV; Prednisolone; Therapy naive HIV patients

Indexed keywords

ANTIRETROVIRUS AGENT; PREDNISOLONE;

ARTICLE; BRAIN DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LOW DRUG DOSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PSYCHOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; VIRUS LOAD;

CD4 LYMPHOCYTE COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV INFECTIONS; HUMANS; MALE; PREDNISOLONE;

EID: 17144424184     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Andrieu JM, Lu W, Levy R (1995) Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J Infect Dis 171: 523-530
2. Andrieu JM, Lu W (2004) Long-term clinical, immunologic and virologic impact of glucocorticoids on the chronic phase of HIV infection. BMC Medicine: 2:17
3. Ascher MS, Sheppard HW (1988) AIDS as immune system activation: a model for pathogenesis. Clin Exp Immunol 73/2:165-167
4. Banda NK, Bernier J, Kurahara DK, Kurrle R, Haigwood N, Sekaly RP, Finkel TH (1992) Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J Exp Med 176: 1099-1104
5. Barinsky IF, Nesterchuk SI (1993) The Effect of Immunocorrectors on HIV-1 Production In Vitro. Antiviral Res 20 Suppl 1: 64
6. Baum LL, Casutt KJ, Knigge K, Khattri R, Margolick J, Rinaldo C, Kleeberger CA, Nishanian P, Henrard DR, Phair J (1996) HIV-1 gp120 specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 157: 2168-2173
7. Blacksin MF, Kloser PC, Simon J (1999) Avascular necrosis of bone in human immunodeficiency virus infected patients. Clin. Imaging 23/5, 314-318
8. Blanche P, Gombert B, Ginsburg C, Passeron A, Stubei I, Rigolet A, Salmon D, Sicard D (1998) HIV combination therapy: immune restitution causing cryptococcal lymphadenitis dramatically improved by anti-inflammatory therapy. Scand J Infect Dis 30/6: 615-616
9. Bressler P, Poli G, Justement JS, Biswas P, Fauci AS (1993) Glucocorticoids synergize with tumor necrosis factor alpha in the induction of HIV expression from a chronicly infected promonocytic cell line. AIDS Res. Hum. Retroviruses 9/6: 547-551
10. Bozzette SA, Sattler FR, Chiu J, Wu AW, Gluckstein D, Kemper C, Bartok A, Niosi J, Abramson I, Coffman J, et al. (1990) A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 323 (21): 1451-1457
11. Burton BJ, Leff AP, Plant GT (1998) Steroid-responsive HIV optic neuropathy. J Neuroophthalmol 18/1: 25-29
12. Christeff N, Gherbi N, Mammes O, Dalle MT, Gharakhanian S, Lortholary O, Melchior JC, Nunez EA (1997) Serum cortisol and DHEA concentrations during HIV infection. Psychoneuroendocrinol 22 Suppl1: 11-18
13. Clerici M, Trabattoni D, Piconi S, Fusi ML, Ruzzante S, Clerici C, Villa ML (1997) A possible role for the cortisol/anticortisols imbalance in the progression of human immunodeficiency virus. Psychoneuroendocrinol 22 Suppl 1: 27-31
14. Dudhane A, Wang ZQ, Orlikowski T, Gupta A, Wormser GP, Horowitz H, Kufer P, Hoffmann MK (1996) AIDS patient monocytes target CD4 T cells for cellular conjugate formation and deletion through the membrane expression of HIV envelope molecules. AIDS Res Hum Retroviruses 12: 893-899
15. Enwonwu CO, Meeks VI, Sawiris PG (1996) Elevated cortisol levels in whole saliva in HIV infected individuals. Eur J Oral Sci 104/3: 322-324
16. Fabricius EM, Hoegl I, Pfaeffl W (1991) Ocular myositis as first presenting symptom of human immunodeficiency virus (HIV-1) infection and its response to high-dose cortisone treatment. Brit J Ophthalm 75: 696-697
17. Findling JW, Buggy BP, Gilson TH, Brummitt CF, Bernstein BM, Raff H (1994) Longitudinal evaluation of adrenocortical function in patients infected with the human immunodeficiency virus. J Clin Endocrinol Metab 79/4: 1091-1096
18. Geusau A, Stingl G (1997) Primary adrenal insufficiency in two patients with the acquired immunodeficiency syndrome associated with disseminated cytomegaloviral infection. Wien Klin Wochenschr 14/109 (21): 845-849
19. Gopal DV, Hassaram S, Marcon NE, Kandel G (1997) Idiopathic colonic inflammation in AIDS: an open trial of prednisone. Am J Gastroenterol 92/12: 2237-2240
20. Jäger H (1994) Adjuvante Kortikoidgabe im Rahmen der HIV-Erkrankung. Indikationen beim Wasting-Syndrom und anderen Erkrankungen im Rahmen von AIDS. Fortschr Med 112: 87-91
21. Justement JS, Poli G, Fauci AS (1990) Glucocorticoids act synergistically with recombinant cytokines to induce HIV expression in chronicly infected promonocyte cells. Int Conf AIDS, Abstract S.A. 322
22. Keiser P, Jockus J, Horton H, Smith JW (1996) Prednisone therapy is not associated with increased risk of herpetic infections in patients infected with human immunodeficiency virus. Clin Infect Dis 23/1: 201-202
23. Kilby JM, Tabereaux PB, Mulanovich V, Shaw GM, Bucy RP, Saag MS (1997) Effects of tapering doses of oral prednisone on viral load among HIV-infected patients with unexplained weight loss. AIDS Res Hum Retroviruses 13/17: 1533-1537
24. Kurata S, Yamamoto N (1999) Glucocorticoid can reduce the transcriptional activation of HIV-1 promoter through the reduction of active NF-kappaB. J Cell Biochem 76/1: 13-19
25. Laudat A, Blum L, Guechot J, Picard O, Cabane J, Imbert JC, Giboudeau J (1995) Changes in systemic gonadal and adrenal steroids in asymptomatic human immunodeficiency virus-infected men: relationship with the CD4 cell counts. Eur J Endocrinol 133/4: 418-424
26. Lu W, Salerno-Goncalves R, Yuan J, Sylvie D, Han DS, Andrieu JM (1995) Glucocorticoids rescue CD4+ T lymphocytes from activation-induced apoptosis triggered by HIV-1: implications for pathogenesis and therapy. AIDS 9/1: 35-42
27. Martos A, Podzamczer D, Martinez-Lacasa J, Rufi G, Santin M, Gudiol F (1995) Steroids do not enhance the risk of developing tuberculosis or other AIDS-related diseases in HIV-infected patients treated for Pneumocystis carinii pneumonia. AIDS 9/9: 1037-1041
28. Norbiato G, Bevilacqua M, Vago T, Clerici M (1998) Glucocorticoid resistance and the immune function in the immunodeficiency syndrome. Ann. N Y Acad. Sci. 1/840: 835-847
29. Nosari AM, Landonio G, Caggese L, Cattaneo D, Muti G, Volonterio A (1994) Thrombotic thrombocytopenic purpura associated with HIV infection: report of two cases. Haematologica 79/3: 280-282
30. Orlikowsky TW, Wang ZQ, Dudhane A, Dannecker GE, Niethammer D, Wormser GP, Hoffmann MK, Horowitz HW (2001) Dexamethasone inhibits CD4 T cell deletion mediated by macrophages from human immunodeficiency virus-infected persons. J Infect Dis 184: 1328-1330
31. Orlikowsky T, Wang ZQ, Dudhane A, Horowitz H, Riethmuller G, Hoffmann MK (1997) Cytotoxic monocytes in the blood of HIV type 1 - infected subjects destroy targeted T cells in a CD95-dependent fashion. AIDS Res Hum Retroviruses 13: 953-960
32. Piedrola G, Casado JL, Lopez E, Moreno A, Perez-Elias MJ, Garcia-Robles R (1996) Clinical features of adrenal insufficiency in patients with acquired immunodeficiency syndrome. Clin Endocrinol (Oxf) 45/1: 97-101
33. Poppinger J (1996) Impact of Palliative Corticoid Therapy in advanced HIV-Disease on HIV I RNA in Plasma. Th.B.195, Int Conf AIDS
34. Rey D, Partisani M, Krantz V, Kempf G, Nicolle M, de Mautort E, Priester M, Bernard-Henry C, Lang JM (1999) Prednisolone does not prevent the occurrence of nevirapine-induced rashes. AIDS 12;13/16, 2307
35. Sapse AT (1997) Cortisol, high cortisol diseases and anticortisol therapy. Psychoneuroendocrinol 22 Suppl 1: 3-10
36. Schramm HJ, Quere L, Buttner J, Wenger T, Dick A, Schramm W (1998) Steroids as possible inhibitors of HIV-1 protease. AIDS 16;12/6: 682-685
37. Skowron G, Cole BF, Zheng D Yen-Lieberman B (1997) pg120-directed antibody-dependent cellular cytotoxicity as a major determant of the rate of decline in CD4 percentage in HIV-1 disease. AIDS 11: 1807-1814
38. Ulmer A (1991) Corticosteroide: Erfahrungen mit dem therapeutischen Einsatz bei verschiedenen Indikationen im Rahmen der HIV-Infektion, in: Jäger H: Die HIV-Erkrankung. Medizinische u. psychosoziale Aspekte zu Beginn der 90er Jahre. Landsberg: Ecomed: 137-138
39. Ulmer A, Bertisch-Möllenhoff B, Wall A, Frietsch B (2001) 5 mg Prednisolon zu Beginn einer Nevirapin-Behandlung. Eur. J. Med. Res. 6 (Suppl I), 90
40. Ulmer WT (1979) Glucocorticoide, in: Ulmer WT: Bronchitis, Asthma, Emphysem, Handbuch der Inneren Medizin 4/2, Berlin: Springer: 732-742
41. 3. J AIDS 32: 281-286
42. Winston JA, Burns GC, Klotman PE (2000) Treatment of HIV-associated nephropathy. Semin Nephrol 20/3: 293-298
43. Zandman-Goddard G, Shoenfeld Y (2002) HIV and autoimmunity. Autoimmun Rev. 1/6: 329-337.